By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Thrombin inhibitors > Bivalirudin > Bivalirudin Dosage
Thrombin inhibitors
https://themeditary.com/dosage-information/bivalirudin-dosage-10844.html

Bivalirudin Dosage

Drug Detail:Bivalirudin (Bivalirudin [ bye-val-i-roo-din ])

Drug Class: Thrombin inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Angina Pectoris

For patients who do not have heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS): 0.75 mg/kg as an IV bolus dose, followed immediately by 1.75 mg/kg/hr IV for the duration of the percutaneous coronary intervention (PCI)/percutaneous transluminal coronary angioplasty (PTCA) procedure; 5 minutes after the bolus dose, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg IV should be given if needed

  • Administration of a glycoprotein IIb/IIIa inhibitor (GPI) should be considered in the event that any of the following conditions are present: decreased TIMI flow (0 to 2) or slow reflow; dissection with decreased flow; new or suspected thrombus; persistent residual stenosis; distal embolization; unplanned stent; suboptimal stenting; side branch closure; abrupt closure; clinical instability; and prolonged ischemia

For patients who have HIT/HITTS undergoing PCI:
0.75 mg/kg IV as a bolus dose, followed immediately by 1.75 mg/kg/hr IV for the duration of the procedure

For ongoing treatment post procedure:
  • The infusion may be continued following PCI/PTCA for up to 4 hours post procedure at the discretion of the physician.
  • In patients with ST segment elevation myocardial infarction (STEMI), continuation of the infusion at a rate of 1.75 mg/kg/hr IV following PCI/PTCA for up to 4 hours post procedure should be considered to mitigate risk of stent thrombosis.
  • After 4 hours, an additional IV infusion may be initiated at a rate of 0.2 mg/kg/hr IV (low-rate infusion) for up to 20 hours, if needed.

Comments:
  • This drug is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Uses:
  • For use as an anticoagulant in patients with unstable angina undergoing PTCA
  • For use an anticoagulant in patients undergoing PCI with provisional use of GPI
  • For use as an anticoagulant in patients with, or at risk of, HIT or HITTS, undergoing PCI

Usual Adult Dose for Percutaneous Coronary Intervention

For patients who do not have heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS): 0.75 mg/kg as an IV bolus dose, followed immediately by 1.75 mg/kg/hr IV for the duration of the percutaneous coronary intervention (PCI)/percutaneous transluminal coronary angioplasty (PTCA) procedure; 5 minutes after the bolus dose, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg IV should be given if needed

  • Administration of a glycoprotein IIb/IIIa inhibitor (GPI) should be considered in the event that any of the following conditions are present: decreased TIMI flow (0 to 2) or slow reflow; dissection with decreased flow; new or suspected thrombus; persistent residual stenosis; distal embolization; unplanned stent; suboptimal stenting; side branch closure; abrupt closure; clinical instability; and prolonged ischemia

For patients who have HIT/HITTS undergoing PCI:
0.75 mg/kg IV as a bolus dose, followed immediately by 1.75 mg/kg/hr IV for the duration of the procedure

For ongoing treatment post procedure:
  • The infusion may be continued following PCI/PTCA for up to 4 hours post procedure at the discretion of the physician.
  • In patients with ST segment elevation myocardial infarction (STEMI), continuation of the infusion at a rate of 1.75 mg/kg/hr IV following PCI/PTCA for up to 4 hours post procedure should be considered to mitigate risk of stent thrombosis.
  • After 4 hours, an additional IV infusion may be initiated at a rate of 0.2 mg/kg/hr IV (low-rate infusion) for up to 20 hours, if needed.

Comments:
  • This drug is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Uses:
  • For use as an anticoagulant in patients with unstable angina undergoing PTCA
  • For use an anticoagulant in patients undergoing PCI with provisional use of GPI
  • For use as an anticoagulant in patients with, or at risk of, HIT or HITTS, undergoing PCI

Renal Dose Adjustments

  • No reduction in the bolus dose is recommended for any degree of renal impairment
  • CrCl less than 30 mL/min: Reduce the infusion dose to 1 mg/kg/hr

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: No change in bolus dose; however, the infusion rate should be reduced to 0.25 mg/kg/hr
Peritoneal dialysis: Data not available

Other Comments

Storage requirements:

  • The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
  • The manufacturer product information should be consulted.

IV compatibility:
  • The manufacturer product information should be consulted.

General:
  • This drug is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by